NASDAQ:XCUR Exicure 6/17/2024 Earnings Report $3.74 -0.14 (-3.61%) As of 02:15 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings History Exicure EPS ResultsActual EPS-$0.10Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AExicure Revenue ResultsActual Revenue$0.50 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AExicure Announcement DetailsQuarterDate6/17/2024TimeN/AConference Call DateN/AConference Call TimeN/AUpcoming EarningsExicure's next earnings date is estimated for Wednesday, November 12, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Exicure Earnings HeadlinesExicure, Inc. Reports Second Quarter 2025 Financial Results | XCUR Stock NewsAugust 8, 2025 | gurufocus.comExicure, Inc. Reports Second Quarter 2025 Financial ResultsAugust 8, 2025 | businesswire.comCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holding investments longer to using tax-advantaged accounts and strategic loss offsetting, there are ways to reduce your exposure. SmartAsset outlines three capital gains tax strategies for seniors and offers a free tool to connect you with vetted fiduciary financial advisors who can help tailor these tactics to your situation.September 19 at 2:00 AM | SmartAsset (Ad)Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing RequirementsAugust 4, 2025 | businesswire.comStocks to Watch: Exicure, TTECAugust 3, 2025 | marketwatch.comExicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous TransplantAugust 1, 2025 | businesswire.comSee More Exicure Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Exicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Exicure and other key companies, straight to your email. Email Address About ExicureExicure (NASDAQ:XCUR) is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system. The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology. By leveraging the unique structural properties of SNA constructs, Exicure aims to improve cellular uptake, enhance pharmacokinetics and reduce off‐target effects compared with traditional nucleic acid therapies. Founded on technology originating from Northwestern University, Exicure is headquartered in Skokie, Illinois, where it conducts its research, preclinical studies and early‐stage development activities. The company completed its initial public offering on the Nasdaq exchange under the ticker XCUR and maintains a focused R&D footprint in the Chicago area. Exicure collaborates with academic institutions and biopharmaceutical partners to advance its SNA platform and expand its therapeutic reach. Guided by a management team with deep expertise in biotechnology innovation, the company is working to translate its nanotechnology into novel treatments for patients with high‐unmet medical needs around the world.View Exicure ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Wall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a Winner Upcoming Earnings Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025)Citigroup (10/14/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
